Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Botox
Biotech
Aeon hits phase 2 goals in rare disorder
Aeon Biopharma's candidate ABP-450 hit its main goals in a phase 2 trial for a rare neck muscle disorder.
Gabrielle Masson
Sep 23, 2022 11:30am
Allergan pays Exicure $25M to discover hair loss drugs
Nov 14, 2019 7:00am
Allergan defuses Botox threat with $195M Bonti buy
Sep 14, 2018 11:15am
Helmed by former Allergan execs, Bonti bags $15M
Jan 24, 2018 10:45am
Evolus plans $75M IPO to bring Botox biosimilar to market
Jan 10, 2018 5:36am
Revance’s rival to Allergan’s Botox aces phase 3
Dec 5, 2017 9:30am
